Articles tagged with Alzheimer Disease
A study by USTC researchers has identified a unique type of neutrophil significantly associated with Alzheimer's disease pathology. The analysis reveals six distinct neutrophil clusters, with the Neu-5 cluster displaying unique characteristics and an altered inflammatory response.
A new study reveals specific brain regions and cell types that are vulnerable to Alzheimer's disease, while others show resilience. Gene expression analysis and lab experiments highlight the role of Reelin in neuronal vulnerability and choline/antioxidants in sustaining cognition.
Scientists successfully mapped transcriptomes from 1.3 million brain cortex cells to gain molecular insights into Alzheimer's vulnerability and resilience. The resulting atlas holds promise for gene and molecular discovery across pathways affecting brain health.
A team of researchers has developed a comprehensive ranking of genes and proteins involved in Alzheimer's disease, providing a roadmap for more targeted research and drug discovery. The study integrates findings from multiple fields and identifies thousands of potential therapeutic targets.
Oligodendrocyte-derived amyloid beta produces toxic peptide that promotes neuronal dysfunction in Alzheimer's disease. Selective suppression of oligodendrocyte Aβ production rescues abnormal neuronal hyperactivity, suggesting targeting these cells as a promising therapeutic strategy for AD.
The A4 study, a large clinical trial of pre-symptomatic Alzheimer’s disease, has yielded key insights into the condition. Researchers have collected extensive data on brain scans, blood samples, genetic information and cognitive tests from over 7,500 participants.
Mayo Clinic scientists have established criteria for a memory-loss syndrome in older adults that specifically impacts the brain's limbic system. The syndrome, called Limbic-predominant Amnestic Neurodegenerative Syndrome (LANS), progresses more slowly and has a better prognosis than Alzheimer's disease.
A new study from Boston University Chobanian & Avedisian School of Medicine found a link between AD pathology and emotional behavioral symptoms. Individuals with AD who decline in memory abilities also experience worsened mental health, which may be due to underlying brain changes.
Researchers at Rice University found that chronic stress impacts cellular health, leading to decreased energy levels and increased inflammation, which can result in dementia, Alzheimer's disease, and other health problems. Caregivers with less leftover cellular energy experience fewer positive emotions and have lower physical functioning.
A new study found that increased exposure to residential greenery during midlife can help stave off cognitive decline. Higher average exposure to greenness was linked to higher levels of cognitive function and slower cognitive decline, particularly among people living in low-socioeconomic status and highly populated neighborhoods.
A retrospective cohort study found hormone-modulating therapy protected against Alzheimer's disease and related dementias in postmenopausal women with breast cancer. The protective effect varied by age and race, with greater benefit for Black women under 75.
A new study published in JAMA Network Open found that hormone modulating therapy (HMT) used to treat breast cancer was associated with a 7% lower risk of developing Alzheimer's disease and related dementias. The protective effect of HMT decreased with age, particularly for women over 80.
Researchers at Boston University Chobanian & Avedisian School of Medicine have found that electroencephalograms (ERPs) can be used to diagnose Amyotid Beta Plaques in patients with Alzheimer's disease. ERPs may provide a low-cost and non-invasive method for detecting AD pathology in-vivo.
A new study published in Cell reveals that the immune protein C1q plays a critical role in neuronal function and aging. In adult mice lacking C1q, there is a significant increase in protein production in neurons, suggesting that C1q may be important for maintaining protein homeostasis in the brain. The study also found that deleting C1...
Researchers investigated the relationship between protein aggregation and liquid-liquid phase separation, finding that droplet formation may actually protect against aggregation. The study, led by Paul Scherrer Institute, used over 500 conditions to test the behavior of alpha-synuclein proteins.
Researchers have developed a multi-component hydrogel scaffold to mimic the amyloid-beta containing microenvironment associated with AD. The study found elevated levels of neuroinflammation and apoptosis markers in healthy neuronal progenitor cells cultured within this environment.
Researchers developed an AI model that accurately predicts Alzheimer's disease progression in 82% of cases, outperforming clinical tests. The model uses cognitive tests and MRI scans to identify individuals at risk, allowing for targeted treatment and closer monitoring.
A study published in Brain Communications found that Alzheimer's patients have a disrupted 'neural clock' in the left angular gyrus, leading to unstable brain activity and cognitive decline. The researchers hope this finding can be used as an early biomarker for detecting the disease.
Researchers have determined the structure of molecules within an Alzheimer's disease brain for the first time using cryo-electron tomography and fluorescence microscopy. This study revealed the molecular structure of tau protein and its arrangement with amyloid plaques, providing new insights into the pathology of the disease.
Researchers analyzed over 1.5 million patient records to find that metformin and SGLT-2 inhibitors lowered dementia and Alzheimer's disease risks compared to other antidiabetic drugs. The study suggests individualized treatment approaches considering patient-specific factors for optimal diabetes management.
Researchers at Amsterdam UMC have developed a prediction model that can forecast cognitive decline in Alzheimer's patients with mild cognitive impairment or dementia. The model provides an indication of the disease course over 5 years and has potential for use in a user-friendly app, aiding doctors in discussing prognosis with patients.
Researchers have discovered an antibody fragment that can bind to abnormal light chains, stabilizing them and preventing their aggregation. This finding has the potential to provide a much-needed treatment for individuals with light chain amyloidosis, which currently has a poor prognosis.
Researchers developed models to predict cognitive decline in people with early Alzheimer's disease. The models showed promise in predicting the rate of decline, but also highlighted the uncertainty of these predictions.
Dr. Rissman's research uses plasma Aβ42/Aβ40 ratio to predict brain amyloid PET positivity and identify individuals at risk for Alzheimer's disease. His findings demonstrate the potential of a blood test to screen for amyloid in preclinical AD trials.
Researchers at Wake Forest University School of Medicine have been awarded a five-year, $27 million grant from the National Institute on Aging to study the connections between heart health and brain health. The study will examine how cardiovascular disease contributes to Alzheimer's disease and other dementias.
Researchers have discovered a new diagnostic method for PSP by analyzing protein biomarkers in spinal fluid, which could lead to earlier diagnosis and targeted therapies. The high-throughput technology allows for the measurement of thousands of proteins in a tiny drop of fluid, providing a promising solution for identifying the condition.
A study found that APOE4 impairs communication between immune cells, leading to cognitive decline in female Alzheimer's patients. The researchers identified a new subset of neutrophils interacting with microglia associated with cognitive impairment, which could be targeted for therapeutic intervention.
Researchers discovered that young adults with higher levels of inflammation were more likely to experience reduced cognitive function in midlife. Higher inflammation was associated with lower performance on skills testing and differences in executive functioning.
A study of 221,777 individuals over 60 years old reveals disparities in antipsychotic use by socioeconomic status. People with low socioeconomic status are more likely to receive antipsychotics for dementia-related symptoms.
A study found that targeting heparan sulfate-modified proteins improves cell repair, rescues neuron loss and reverses cellular changes associated with neurodegenerative diseases. Disrupting these proteins promotes autophagy-dependent cell repair and reverses early cellular problems in models of Alzheimer's.
A recent study proposes a multi-dimensional approach to map disease relationships using genomic, chemical, and clinical data. The research reveals significant distinctions from the classical International Classification of Diseases system and highlights potential links between previously separate conditions.
Alzheimer's patients' samples exhibit altered communication between pericytes and astrocytes, mediated by VEGFA and SMAD3. Donors with higher blood SMAD3 levels had less vascular damage and better outcomes.
Researchers at Boston University developed an AI model that analyzes speech patterns to predict the likelihood of Alzheimer's disease in patients with mild cognitive impairment. The model achieved an accuracy rate of 78.5% and could potentially revolutionize dementia screening, making it more accessible and efficient.
A new study by Dr. Peter Lichtenberg and his team found that early memory loss is linked to excess spending in older adults. The WALLET Study analyzed bank statements to identify financial behaviors associated with excess spending, providing valuable insights into the intersection of financial risk and cognitive decline.
Researchers have developed a new nonhuman primate model that allows for the tracking and treatment of early-stage Alzheimer's disease. The study shows a six-month window in which disease progression can be measured, enabling preclinical testing of interventions targeting the tau protein.
Researchers found a causal link between cerebral small-vessel disease and increased risk of Alzheimer's and dementia. The study highlights the importance of white matter hyperintensity burden as a surrogate marker for clinical trials to prevent dementia.
A new study identifies a strong recessive component in Alzheimer's disease, with high risks in homozygotes and compound heterozygotes. The R47H variant in the TREM2 gene disrupts Aβ clearance, leading to amyloid plaque accumulation and increased risk of Alzheimer's.
Researchers found that women who had their ovaries removed before menopause experience reduced white matter integrity in multiple brain regions. This reduction may contribute to an increased risk of cognitive decline and dementia later in life.
Scientists have discovered a new insight into why some people are more susceptible to Alzheimer’s disease. The study reveals how the interaction between the APOE gene and Aβ protein influences our likelihood of developing Alzheimer's disease, with the APOE4 variant increasing risk significantly.
Researchers at OIST have discovered a novel treatment that effectively reverses the symptoms of Alzheimer's disease in mice. The treatment, PHDP5, targets the dynamin-microtubule interaction and restores communication between neurons inside synapses.
Researchers found that carrying just one copy of the Christchurch variant delayed cognitive decline and dementia in family members, with some showing lower levels of tau proteins. The study suggests potential benefits for drug development targeting this genetic pathway.
Two studies by Prof. Lucía Chávez Gutiérrez's team reveal the role of gamma-secretase inhibition and amyloid plaque composition in AD. Aβ42 fragments impede gamma-secretase function, while multimodal mass spectrometry imaging reveals diverse plaque compositions.
Dorothee Dormann and Edward Lemke propose a new concept to measure the individual risk of getting age-related diseases by analyzing protein clumps in cells. This 'protein aggregation clock' could help diagnose age-related diseases at early stages or identify people at higher risk.
A recent study by Mass General Brigham researchers found that adults with a family history of Alzheimer's disease on their mother's side had higher amyloid levels in their brains. This suggests that maternal inheritance may play a role in identifying individuals at heightened risk for developing the disease.
Researchers used machine learning to integrate high-throughput transcriptomic, proteomic, metabolomic, and lipidomic profiles to identify four distinct molecular profiles of Alzheimer's Disease. These profiles were associated with varying levels of cognitive function and neuropathological features.
A suite of three innovations by MIT researchers allows for high-resolution, high-throughput imaging of human brain tissue at various scales. This technology pipeline enables scientists to analyze the human brain at multiple scales, potentially mapping entire brains.
A new study led by Chapman University researchers found that combining Donepezil and Memantine significantly increased the probability of five-year survival for Alzheimer's disease patients. The combined use of these two medications reduced mortality rates by 0.05, or 6.4%, compared to no treatment and single-drug use.
Researchers led by Dr. Victor Luna aim to develop new treatments for late-life depression and Alzheimer's disease by understanding how synapses function in the aging brain. They will investigate the role of a synaptic protein called mGluR2 in memory formation and emotion.
Researchers from Tokyo Medical and Dental University used long-read RNA sequencing to decode genetic intricacies and disease links. The study identified novel isoforms, cell-type-specific splicing patterns, and disease-linked transcripts associated with immune-related diseases.
Researchers developed an AI-based screening tool that differentiates Alzheimer's disease and Lewy body disease by analyzing eye movement patterns. The tool provides a reliable method for identifying and distinguishing between the two dementia forms, which can aid in mitigating their impact on daily activities.
The study highlights the potential of omics research and AI tools to disentangle the molecular drivers of Alzheimer’s disease. Key findings include the identification of novel biomarkers for early detection and therapeutic targets, as well as the exploration of genetic factors contributing to AD risk and progression.
Middle-aged people exhibit reduced exploration when learning a novel maze environment compared to younger individuals. This difference is partially driven by changes in how they learn about the maze, including visiting more objects and pausing for longer periods.
Researchers estimate that 32% of memory clinic attendees and 14% of specialist cognitive service patients are eligible for disease-modifying therapies. Biomarker testing is crucial to identify suitable patients, but only a minority have undergone tests.
New Alzheimer's drugs aim to halt condition progression, but UK patients may face limited eligibility due to lack of biomarker testing and diagnostic scans. The study suggests that over 20,000 people per year will need access to confirmatory investigations to determine suitability for treatment.
Dr. Jeetain Mittal's NIH grant will support multiscale computational models investigating phase separation in biology, particularly heterochromatin formation and its role in neurodegenerative diseases. The research aims to elucidate the molecular origins of phase separation using innovative models and methods.
Nutrition 2024 will explore the role of diet in exercise performance, brain health, and disease prevention. Researchers will share emerging findings on the relationships between specific foods and chronic diseases.
A comprehensive, user-friendly repository has been created to help study Alzheimer's disease. The ssREAD database encompasses 277 integrated datasets from 67 scRNA-seq & snRNA-seq studies, totaling 7,332,202 cells, and includes interactive visualizations for comprehensive analysis interpretations.
A new study from Wake Forest University School of Medicine suggests that vigorous physical activity can lower the risk of cognitive decline in high-risk patients with hypertension. People who engage in one or more sessions of vigorous exercise per week had lower rates of mild cognitive impairment and dementia.
The study identified 99 RNA isoforms that were either increased or decreased in Alzheimer's brains, even when overall gene activity didn't change. This discovery shows the importance of understanding isoforms and their unique functions in a gene along with their roles in human health and disease.
Researchers at Queen Mary University of London developed a predictive test using fMRI scans that detects changes in the brain's 'default mode network' to predict dementia. The test showed accurate predictions up to nine years before an official diagnosis, with greater than 80% accuracy and a two-year margin of error.